Carthagenetics

Founded in 2004 CarthaGenetics® provides specialized consulting services for companies developing rare disease treatments, advanced therapies, and orphan drugs seeking to navigate the complex European markets (including Turkey) and the expanding North African region. The company's name draws inspiration from ancient Carthage – renowned for innovation and Hannibal's legendary elephant-led expedition across the Alps – symbolizing the company's commitment to finding unconventional pathways for rare disease treatments. Founded by Philippe Carteron de Balmont based on his personal commitment to improving access to orphan disease treatments, CarthaGenetics® has collaborated with the most prestigious biotech and pharmaceutical companies in the rare disease space, including Alexion, Alnylam, Amicus, Biogen, BioMarin, FoldRX/Pfizer, Genzyme, Horizon, Insmed, Orchard, PTC, RegenXbio, Shire, and Ultragenyx. The company has also provided expert consultation to governmental organizations such as the Turkish Ministry of Health and the Turkish Pharmacist Association (TEB). With a dedicated team of professionals, CarthaGenetics® focuses exclusively on innovative medicines, including cell and gene therapies, offering three core areas of expertise: - 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀: Development of comprehensive pre-launch and launch strategies for orphan drugs, including regulatory pathway navigation, pricing and reimbursement planning, and stakeholder mapping. - 𝗘𝗮𝗿𝗹𝘆 𝗔𝗰𝗰𝗲𝘀𝘀 𝗣𝗿𝗼𝗴𝗿𝗮𝗺𝘀: Implementation of named-patient sales initiatives, compassionate use programs, and other early access mechanisms that provide treatment options for patients prior to full regulatory approval. - 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗧𝗿𝗶𝗮𝗹 𝗦𝘂𝗽𝗽𝗼𝗿𝘁: Patient identification and recruitment for clinical trials in rare diseases, leveraging deep relationships with specialist physicians and patient advocacy groups.